1. Pfizer spending a pot ‘o gold in Dublin

Ahhhhh, the lure of low corporate taxes. According to The Irish Times, Pfizer will be spending €300-400 million to expand manufacturing capabilities in its legacy Wyeth plant located in Ireland’s capital city. In spite of almost certain future competition from biosimilars, it seems Pfizer expects demand for its biologics to increase, including Enbrel—the Rheumatoid Arthritis blockbuster—and Prevnar—the vaccine for things we can pronounce but not spell. Increasing capacity to manufacture biologics is not quick. Pfizer expects to have the facility operational by 2020.